Eisai CoTSE:4523 +1.92%62 Market Cap is 円1,159,708 Mil as of Jul. 02, 2026. GuruFocus rates TSE:4523 with a GF Score™ of 62/100 and a GF Value™ of 円5,710.56 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Eisai Co ranks better than 93.95% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Eisai Co's share price for the quarter that ended in Mar. 2026 was 円4871. Eisai Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 282 Mil. Therefore, Eisai Co's market cap for the quarter that ended in Mar. 2026 was 円1,373,091 Mil.
Eisai Co's quarterly market cap
declined
from Sep. 2025 (円1,402,408 Mil) to Dec. 2025 (円1,313,612 Mil) but then
increased
from Dec. 2025 (円1,313,612 Mil) to Mar. 2026 (円1,373,091 Mil).
Eisai Co's annual market cap
declined
from Mar. 2024 (円1,781,059 Mil) to Mar. 2025 (円1,168,426 Mil) but then
increased
from Mar. 2025 (円1,168,426 Mil) to Mar. 2026 (円1,373,091 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eisai Co's Enterprise Value for Today is 円1,125,605 Mil.
Eisai Co (TSE:4523) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Eisai Co Market Cap Related Terms
Eisai Co Market Cap Historical Data
* Premium members only.
The historical data trend for Eisai Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Eisai Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Eisai Co's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (TSE:4523) has a Market Cap of 円1,159,708 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eisai Co and its competitors. According to the industry distribution chart, Eisai Co ranks #62 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 6.1%.
Is Eisai Co's Market Cap too high?
Eisai Co's current Market Cap is 円1,159,708 Mil. Based on the distribution chart, Eisai Co ranks #62 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eisai Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #62 out of 1024 companies for Market Cap. This places Eisai Co in the top 6% of its industry — outperforming the majority of peers. The industry median Market Cap is 212.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.74, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Market Cap is 円1,159,708 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (TSE:4523) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,710.56, compared to a current price of 円4,188.00 — trading 26.7% below its estimated fair value. The current Market Cap is 円1,159,708 Mil. Eisai Co's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Eisai Co (TSE:4523), the current Market Cap is 円1,159,708 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (TSE:4523) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of 円4,188.00 is trading 26.7% below its estimated GF Value™ of 円5,710.56.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for TSE:4523:
Market Cap: 円1,159,708 Mil
GF Value™: 円5,710.56 vs. price of 円4,188.00 (26.7% below fair value)
No single metric tells the full story. See the TSE:4523 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
62GF Score
Get the complete analysis for TSE:4523
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4523 has been successfully added to your 
